Welcome to our dedicated page for OmniAb SEC filings (Ticker: OABI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OmniAb, Inc. filings document the public-company disclosures of an antibody discovery technology business that licenses its platform to pharmaceutical, biotechnology and academic partners. Its Form 8-K reports furnish operating and financial results, partner program updates, guidance-related disclosures and other material events tied to the company’s licensing, service, milestone and royalty model.
The company’s proxy and governance filings cover annual meeting matters, director elections, auditor ratification, shareholder voting results and bylaw amendments addressing proxy-solicitation procedures and stockholder proposal mechanics. OmniAb filings also identify its emerging growth company status, Nasdaq-listed common stock and warrants, and recurring capital-structure and governance disclosure topics.
Form 4 filing for OmniAb, Inc. (OABI) dated 18-Jun-2025 discloses equity transactions by director Carolyn R. Bertozzi on 17-Jun-2025.
- Common stock: 20,000 shares were acquired upon vesting of previously granted restricted stock units (RSUs). Post-transaction direct ownership stands at 75,539 shares.
- New equity grants: (i) 20,000 RSUs, each convertible into one common share, and (ii) a stock option for 40,000 shares with a $1.70 exercise price and 17-Jun-2035 expiration. All new awards vest in full on the earlier of the next annual shareholder meeting or the first anniversary of the 17-Jun-2025 grant date.
- No dispositions of shares occurred; all reported transactions increase or maintain the insider’s exposure to OmniAb’s equity.
These routine director equity awards and vesting events align incentives with shareholders and do not, by themselves, alter OmniAb’s fundamentals. The filing satisfies Section 16 reporting obligations and contains no indications of sales, pledges, or derivative hedging.